Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP4 | P15090 | 2/20 | 0.65 |
| ▸ | TAS2R14 | Q9NYV8 | 6/20 | 0.62 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.62 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.62 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.62 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.62 |
| ▸ | CTSV | O60911 | 1/20 | 0.57 |
| ▸ | CTSL | P07711 | 1/20 | 0.57 |
| ▸ | MPO | P05164 | 1/20 | 0.57 |
| ▸ | TTR | P02766 | 1/20 | 0.55 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.54 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.54 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.53 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7572551 | 0.89 | CXCR2 (0.63) | FABP4TAS2R14PTGS1AKR1C3AKR1C2 | |
| SCHEMBL338231 | 0.86 | P2RX1 (0.62) | SIRT2SIRT1ALDH1A1P2RX1HTT | |
| SCHEMBL28660772 | 0.83 | MAPT (0.69) | PTGS2SIRT2SIRT1ALDH1A1P2RX1 | |
| Fenamic Acid SCHEMBL25828 | 0.82 | FABP4 (0.92) | FABP4TAS2R14PTGS1AKR1C3AKR1C2 | |
| Fenamic Acid SCHEMBL29622832 | 0.82 | FABP4 (0.92) | FABP4TAS2R14PTGS1AKR1C3AKR1C2 | |
| SCHEMBL15673372 | 0.82 | SIRT2 (0.77) | FABP4TAS2R14PTGS1AKR1C3AKR1C2 | |
| SCHEMBL2294168 | 0.82 | AKR1C3 (0.67) | FABP4TAS2R14PTGS1AKR1C3AKR1C2 | |
| SCHEMBL9719838 | 0.82 | FABP4 (0.67) | FABP4TAS2R14PTGS1AKR1C3AKR1C2 | |
| SCHEMBL383535 | 0.82 | GRIK1 (0.74) | AKR1C3AKR1C2MPOGRIK1GRIK2 | |
| SCHEMBL15397409 | 0.82 | AKR1C3 (0.60) | AKR1C3AKR1C2MPOGRIK1GRIK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130310411-A1 | NOVEL ACRIDINE DERIVATIVES | PHARMINOX LIMITED (GB) | 2013-11-21 | — | — | US | disclosed |
| EP-2621929-A1 | NOVEL ACRIDINE DERIVATIVES | Pharminox Limited (GB) | 2013-08-07 | — | — | EP | disclosed |
| WO-2012042265-A1 | NOVEL ACRIDINE DERIVATIVES | PHARMINOX LIMITED (GB) | 2012-04-05 | — | — | WO | disclosed |
| EP-1330456-B8 | N8,N13 -DISUBSTITUTED QUINO[4,3,2-KL]ACRIDINIUM SALTS AS THERAPEUTIC AGENTS | CANCER REC TECH LTD (GB) | 2012-02-08 | — | — | EP | disclosed |
| EP-1330456-B9 | N8,N13 -DISUBSTITUTED QUINO[4,3,2-KL]ACRIDINIUM SALTS AS THERAPEUTIC AGENTS | CANCER REC TECH LTD (GB) | 2012-01-25 | — | — | EP | disclosed |
| EP-1330456-B9 | N8,N13 -DISUBSTITUTED QUINO[4,3,2-KL]ACRIDINIUM SALTS AS THERAPEUTIC AGENTS | CANCER REC TECH LTD (GB) | 2012-01-25 | — | — | EP | disclosed |
| EP-1330456-B1 | N8,N13 -DISUBSTITUTED QUINO[4,3,2-KL]ACRIDINIUM SALTS AS THERAPEUTIC AGENTS | CANCER REC TECH LTD (GB) | 2011-06-15 | — | — | EP | disclosed |
| EP-1330456-B1 | N8,N13 -DISUBSTITUTED QUINO[4,3,2-KL]ACRIDINIUM SALTS AS THERAPEUTIC AGENTS | CANCER REC TECH LTD (GB) | 2011-06-15 | — | — | EP | disclosed |
| US-7115619-B2 | N8, N13 -disubstituted quino[4,3,2-kl]acridinium salts as therapeutic agents | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2006-10-03 | — | — | US | disclosed |
| US-20040063739-A1 | N8, n13 -disubstituted quino[4,3,2-kl]acridinium salts as therapeutic agents | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2004-04-01 | — | — | US | disclosed |
| EP-1330456-A2 | N8,N13 -DISUBSTITUTED QUINO 4,3,2-KL]ACRIDINIUM SALTS AS THERAPEUTIC AGENTS | Cancer Research Technology Limited (GB) | 2003-07-30 | — | — | EP | disclosed |
| WO-2002030932-A2 | N8,N13-DISUBSTITUTED QUINO[4,3,2-KL]ACRIDINIUM SALTS AS THERAPEUTIC AGENTS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2002-04-18 | — | — | WO | disclosed |
| US-4168312-A | Quinolone derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1979-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310411-A1 | NOVEL ACRIDINE DERIVATIVES | TERT, NAT10, POT1 | FABP4 4106/4885TAS2R14 3547/4885PTGS1 2166/4885 |
| US-20040063739-A1 | N8, n13 -disubstituted quino[4,3,2-kl]acridinium salts as therapeutic agents | TERT, MKI67, NQO2 | FABP4 4772/4885TAS2R14 2367/4885PTGS1 3003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.